S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
NASDAQ:VTYX

Ventyx Biosciences (VTYX) Stock Price, News & Analysis

$4.47
+0.12 (+2.76%)
(As of 04/19/2024 ET)
Today's Range
$4.26
$4.63
50-Day Range
$2.29
$10.13
52-Week Range
$1.87
$40.58
Volume
906,049 shs
Average Volume
1.23 million shs
Market Capitalization
$315.14 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.75

Ventyx Biosciences MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.56 Rating Score
Upside/​Downside
386.6% Upside
$21.75 Price Target
Short Interest
Healthy
19.58% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.07mentions of Ventyx Biosciences in the last 14 days
Based on 12 Articles This Week
Insider Trading
Selling Shares
$39,787 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.55) to ($2.47) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.67 out of 5 stars

Medical Sector

416th out of 907 stocks

Pharmaceutical Preparations Industry

188th out of 424 stocks

VTYX stock logo

About Ventyx Biosciences Stock (NASDAQ:VTYX)

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.

VTYX Stock Price History

VTYX Stock News Headlines

Now Open: Crypto emergency update
During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.
Now Open: Crypto emergency update
During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.
See More Headlines
Receive VTYX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ventyx Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/27/2024
Today
4/21/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:VTYX
Fax
N/A
Employees
79
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$21.75
High Stock Price Target
$62.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+386.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.56
Research Coverage
9 Analysts

Profitability

Net Income
$-192,960,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$4.13 per share

Miscellaneous

Free Float
53,304,000
Market Cap
$315.14 million
Optionable
Optionable
Beta
0.27
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

VTYX Stock Analysis - Frequently Asked Questions

Should I buy or sell Ventyx Biosciences stock right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ventyx Biosciences in the last twelve months. There are currently 4 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" VTYX shares.
View VTYX analyst ratings
or view top-rated stocks.

What is Ventyx Biosciences' stock price target for 2024?

9 brokerages have issued 12 month price targets for Ventyx Biosciences' shares. Their VTYX share price targets range from $5.00 to $62.00. On average, they predict the company's share price to reach $21.75 in the next twelve months. This suggests a possible upside of 386.6% from the stock's current price.
View analysts price targets for VTYX
or view top-rated stocks among Wall Street analysts.

How have VTYX shares performed in 2024?

Ventyx Biosciences' stock was trading at $2.47 at the beginning of 2024. Since then, VTYX stock has increased by 81.0% and is now trading at $4.47.
View the best growth stocks for 2024 here
.

When is Ventyx Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our VTYX earnings forecast
.

How were Ventyx Biosciences' earnings last quarter?

Ventyx Biosciences, Inc. (NASDAQ:VTYX) announced its earnings results on Tuesday, February, 27th. The company reported ($0.79) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.87) by $0.08. During the same quarter last year, the company posted ($0.62) earnings per share.

What ETF holds Ventyx Biosciences' stock?

iShares U.S. Pharmaceuticals ETF holds 39,340 shares of VTYX stock, representing 0.35% of its portfolio.

When did Ventyx Biosciences IPO?

Ventyx Biosciences (VTYX) raised $152 million in an IPO on Thursday, October 21st 2021. The company issued 9,472,656 shares at $15.00-$17.00 per share.

Who are Ventyx Biosciences' major shareholders?

Ventyx Biosciences' stock is owned by many different institutional and retail investors. Top institutional investors include Norden Group LLC (0.02%). Insiders that own company stock include Christopher W Krueger, Global Strategic Fund I Venbio, John Nuss, Martin Auster, Nsv Partners Iii Lp, Raju Mohan, Sheila Gujrathi, Somu Subramaniam, William J Sandborn and William Richard White.
View institutional ownership trends
.

How do I buy shares of Ventyx Biosciences?

Shares of VTYX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:VTYX) was last updated on 4/21/2024 by MarketBeat.com Staff

From Our Partners